drugset / Trial / NCT01417156

Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)

NCT01417156

Phase 2 Completed 20 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

Primary objective of this study is to investigate the long-term tolerability and safety profile of BIBF 1120 on top of pirfenidone treatment in patients with Idiopathic Pulmonary Fibrosis who have completed a prior clinical trial of BIBF 1120 (1199.31). Secondary objectives are to assess effects on some efficacy criteria during long term treatment with BIBF 1120 on top of pirfenidone.

Timeline

Start
2011-09
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Nintedanib Small molecule 150 mg Oral
Background Pirfenidone Small molecule

Indications